Current treatments for IBD focus on suppressing inflammation or modulating the immune response using corticosteroids, mercaptopurines, 5-ASA, or monoclonal antibodies against inflammatory cytokines, e.g., the anti-tumor necrosis factor (TNF)-α antibody infliximab (3). This evidence concerns the gene TNF and inflammatory bowel disease.